巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    虛擬市場

    Entera Bio Ltd

    ENTX
    1.650
    ▲0.040
    ▲2.48%
    概況消息
    最少15分鐘延遲，股票資訊由第三方資訊供應商提供
    ・Entera Bio Ltd - 延遲價格・最後更新於 24/06 12:15
    最高位
    1.650
    最低位
    1.540
    開市價
    --
    前收市價
    1.610
    成交量(千)
    0.12
    成交額(百萬)
    0.00
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    47.54
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    6.600 - 1.430
    所有資料不保證絕對正確、完整、或實時，僅作為參考使用。投資涉及風險，過往業績並不代表將來表現，作任何投資決定或交易前，閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Entera Bio Ltd
    證券代碼
    ENTX.US
    所屬板塊
    Biotechnology
    公司業務
    Entera Bio Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The company's product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The company recently completed the phase 2 study for EB613. The company also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.
    發行量
    28804411
    公司總部
    Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem Bio Park
    公司網址
    https://www.enterabio.com
    公司電郵
    phillip@enterabio.com
    公司電話
    +972 25327151

    最新發佈

    暫無內容

    關於

    Entera Bio Ltd(ENTX.US)所屬的行業板塊為Biotechnology。
    Entera Bio Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The company's product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The company recently completed the phase 2 study for EB613. The company also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.
    詳細公司背景可參考: https://www.enterabio.com。